Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

A shot that could shield healthcare workers from a silent killer

NCT ID NCT04072211

Prevention Sponsor: Centre for Infectious Disease Research in Zambia Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 10, 2026 · Last updated Aug 11, 2026 · Updated 1 time

Summary

This trial tests whether a three-dose hepatitis B vaccine can protect healthcare workers in Zambia from infection. The vaccine is given at 0, 1, and 6 months, and blood tests measure the immune response. The goal is to see if the vaccine produces protective antibodies and cellular immunity in this high-risk group.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Hepatitis B vaccine (Engerix-B)
What this could lead to
If successful, this could show that vaccinating healthcare workers in high-risk areas effectively prevents hepatitis B infection, potentially reducing disease spread.
What could go wrong
The trial is a demonstration project, so it may not prove long-term protection. Some people may not develop adequate immunity, and the vaccine can cause mild side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

641 people

The number who actually took part.

Started

Nov 2019

Finished

Aug 2020

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Aged ≥18 years * Willing to consent and meet project requirements for training and follow-up. Exclusion Criteria: * Kidney disease or renal failure * Pregnant * History or current neurological condition * Express refusal to consent

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Health care associated infection are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

nosocomial infection hepatitis B virus infection prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Health care associated infection Hepatitis B virus

Contacts and locations

Locations

  • Kalulushi district all facilities

    Kalulushi, Copperbelt, 10101, Zambia

More trials for these conditions

Other studies related to the condition(s) this trial covers.